These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 7599335)

  • 41. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Prophylaxis and therapy of gastropathy caused by non-steroidal anti-inflammatory drugs].
    László A
    Orv Hetil; 2002 Jul; 143(27):1643-8. PubMed ID: 12180001
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The role of anti-ulcerative drugs in treatment and prevention of gastropathies induced by nonsteroidal anti-inflammatory drugs].
    Fialová P; Vlcek J
    Vnitr Lek; 2004 Nov; 50(11):858-66. PubMed ID: 15648967
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Prostaglandins and the prevention of non-steroidal antirheumatic drug-induced gastric lesions].
    Miederer SE
    Fortschr Med; 1989 Mar; 107(10):63-4, 67-8. PubMed ID: 2497057
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment of peptic ulcer related to rheumatic diseases].
    Imaeda H; Ishii H; Goto M
    Nihon Rinsho; 2002 Aug; 60(8):1585-91. PubMed ID: 12187755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The therapeutic efficacy of misoprostol in peptic ulcer disease.
    Watkinson G; Hopkins A; Akbar FA
    Postgrad Med J; 1988; 64 Suppl 1():60-77. PubMed ID: 3138682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Proton pump inhibitor H2 receptor antagonist].
    Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
    Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy.
    Lanas A; Remacha B; Sáinz R; Hirschowitz BI
    Am J Gastroenterol; 2000 Feb; 95(2):513-9. PubMed ID: 10685760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers.
    Musumba C; Pritchard DM; Pirmohamed M
    Aliment Pharmacol Ther; 2009 Sep; 30(6):517-31. PubMed ID: 19575764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.
    La Corte R; Caselli M; Castellino G; Bajocchi G; Trotta F
    Drug Saf; 1999 Jun; 20(6):527-43. PubMed ID: 10392669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Challenges in managing NSAID-associated gastrointestinal tract injury.
    Goldstein JL
    Digestion; 2004; 69 Suppl 1():25-33. PubMed ID: 15001832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Recommendation for the prevention and treatment of non-steroidal anti-inflammatory drug-induced gastrointestinal ulcers and its complications].
    ;
    Zhonghua Nei Ke Za Zhi; 2017 Jan; 56(1):81-85. PubMed ID: 28056333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine.
    Miyake K; Ueki N; Suzuki K; Shinji Y; Kusunoki M; Hiratsuka T; Nishigaki H; Tatsuguchi A; Futagami S; Wada K; Tsukui T; Nakajima A; Yoshino S; Sakamoto C
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():67-72. PubMed ID: 15943850
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Treatment of nonsteroidal anti-inflammatory drug-associated gastric and duodenal damage. Efficacy of antisecretory drugs and mucosal protective compounds.
    Pipkin G; Mills JG
    Dig Dis; 1995 Jan; 13 Suppl 1():75-88. PubMed ID: 7697904
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Misoprostol prevents NSAID-induced gastroduodenal lesions in patients with osteoarthritis and rheumatoid arthritis.
    Saggioro A; Alvisi V; Blasi A; Dobrilla G; Fioravanti A; Marcolongo R
    Ital J Gastroenterol; 1991; 23(3):119-23. PubMed ID: 1742504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Agents used in the prevention and treatment of nonsteroidal anti-inflammatory drug-associated symptoms and ulcers.
    Scheiman J; Isenberg J
    Am J Med; 1998 Nov; 105(5A):32S-38S. PubMed ID: 9855174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy.
    Yeomans ND
    Ital J Gastroenterol Hepatol; 1999; 31 Suppl 1():S89-92. PubMed ID: 10379475
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NSAID-induced gastrointestinal toxicity.
    Simon LS; Goodman T
    Bull Rheum Dis; 1995 May; 44(3):1-5. PubMed ID: 7767404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.